MedTrace Logo

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents

NCT00518180 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1620

Last updated 2016-05-18

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine when administered with Tdap and HPV vaccinations to healthy adolescents

Conditions

  • Meningococcal Meningitis
  • Human Papillomavirus Infection
  • Pertussis
  • Tetanus

Interventions

BIOLOGICAL

Novartis Meningococcal ACWY Conjugate Vaccine

One dose of vaccine administered intramuscularly

BIOLOGICAL

Tdap Vaccine

One dose of vaccine administered intramuscularly

BIOLOGICAL

Novartis Meningococcal ACWY Conjugate Vaccine

One dose of vaccine administered intramuscularly

Sponsors & Collaborators

  • Novartis Vaccines

    lead INDUSTRY

Principal Investigators

  • Novartis Vaccines and Diagnostics · Novartis

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
11 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-04-30
Completion
2008-10-31

Countries

  • Costa Rica

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00518180 on ClinicalTrials.gov